-+ 0.00%
-+ 0.00%
-+ 0.00%
Kangchen Pharmaceutical (603590.SH): KC1101 project obtained clinical trial notice
Share
Listen to the news

Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company received a clinical trial notice for the Class 1 innovative chemical drug KC1101 tablets approved and issued by the State Drug Administration. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. It is intended for the treatment of advanced recurrent or metastatic solid tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending